您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > (±)-CP 55,940-d11
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(±)-CP 55,940-d11
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(±)-CP 55,940-d11图片
规格:98%
分子量:387.6
包装与价格:
包装价格(元)
100ug电议
500ug电议
1mg电议

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx20864
CAS:N/A
分子式:C24H29D11O3
分子量:387.6
溶解度:DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

(±)-CP 55,940-d11is intended for use as an internal standard for the quantification of (±)-CP 55,940 by GC- or LC-MS. (±)-CP 55,940 is a potent, non-selective cannabinoid (CB) receptor agonist (Kis = 5 and 1.8 nM for human CB1and CB2, respectively).1It stimulates [35S]GTPγS binding to rat cerebellar membranes (EC50s = 0.22-0.96 nM).2In vivo, (±)-CP 55,940 induces analgesia in the tail clamp, hot plate, tail flick, flinch jump, and PBQ-induced writhing tests with 50% maximum possible effect (MPE50) values of 0.46, 1.11, 0.55, 0.63, and 0.29 mg/kg, respectively.3(±)-CP 55,940 also decreases the discrimination index (DI) of female, but not male, rats in the object location task as well as the DI of male, but not female, rats in the novel object recognition task.4


1.Pertwee, R.G.Pharmacology of cannabinoid receptor ligandsCurr. Med. Chem.6(8)635-664(1999) 2.Griffin, G., Atkinson, P.J., Showalter, V.M., et al.Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranesJ. Pharmacol. Exp. Ther.285(2)553-560(1998) 3.Howlett, A.C., Johnson, M.R., Melvin, L.S., et al.Nonclassical cannabinoid analgetics inhibit adenylate cyclase: Development of a cannabinoid receptor modelMol. Pharmacol.33(3)297-302(1987) 4.Mateos, B., Borcel, E., Loriga, R., et al.Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB1 cannabinoid receptorsJ. Psychopharmacol.25(12)1676-1690(2011)